Quality of life (QOL) of patients with autosomal dominant polycystic kidney disease (ADPKD): Influence of renal TAE or hepatic TAE on QOL.

Quality of life (QOL) of patients with autosomal dominant polycystic kidney disease (ADPKD): Influence of renal TAE or hepatic TAE on QOL. - Toranomon PKD QOL study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007623

Enrollment

500

Registered

2012-03-30

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal dominant polycystic kidney disease (ADPKD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with ADPKD referred to Toranomon Hospital from March 2010.

Exclusion criteria

Exclusion criteria: Patients who received renal or hepatic TAE before March 2010 or patients who did not agree to participate in this research were excluded.

Design outcomes

Primary

Measure	Time frame
Physical component summary (PCS), mental component summary (MCS), and role/social component summary (RCS) of the Short Form-36 (SF-36) version 2.	—

Secondary

Measure	Time frame
Ten questions about specific symptoms in patients with ADPKD, such as abdominal distension, poor appetite, and sleep disturbance.	—

Countries

Japan

Contacts

Public ContactTatsuya Suwabe

Toranomon Hospital Department of Nephrology

suwabe@toranomon.gr.jp044-877-5111

Outcome results